Study Explores Empagliflozin’s Potential Benefits for Liver Health in Patients with Type 2 Diabetes and NAFLD

A recent study has examined the effects of empagliflozin, a medication commonly used to manage Type 2 diabetes, on liver health in patients with non-alcoholic fatty liver disease (NAFLD). The research, conducted by Erfanifar et al., highlights the potential impact of this glucose-lowering drug beyond its primary purpose. The findings suggest that empagliflozin may play a role in addressing liver-related complications often associated with diabetes.

The study focused on individuals diagnosed with both Type 2 diabetes and NAFLD, a condition characterized by excessive fat accumulation in the liver not caused by alcohol consumption. Researchers evaluated how empagliflozin affected markers of liver health and metabolic function. While traditionally prescribed to help regulate blood sugar levels, the investigation explored whether the drug could also improve liver-related outcomes in this patient population. Further details about the methodology and specific results were not disclosed in the initial report.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

Author

GOAI